Photo via South China Morning Post

US firm ArriVent’s plunge shows risks facing China’s biotech expansion into global markets

Read the original at South China Morning Post ↗
Cite

Shen, X. (2026, October 7). US firm ArriVent’s plunge shows risks facing China’s biotech expansion into global markets. South China Morning Post. https://www.scmp.com/business/china-business/article/3369985/us-firm-arrivents-plunge-shows-risks-facing-chinas-biotech-expansion-global-markets?utm_source=rss_feed

Dated when The Aporia collected the article, usually within hours of publication. Check the original for its exact date and byline.

South China Morning Post · collected 2026-10-07 · by Xinmei Shen

Quick Summary

ArriVent BioPharma's stock dropped nearly 47% after a late-stage trial for its cancer drug firmonertinib failed to meet primary goals. The drug was originally developed by Shanghai Allist Pharmaceuticals and licensed by ArriVent in 2021 to treat non-small cell lung cancer with an epidermal growth factor receptor exon 20 insertion mutation. This setback underscores the challenges Chinese biotech firms face when expanding into global markets through partnerships with US companies.
Written by AI on 2026-10-07, from this article's own text only (the story summary below draws on all the coverage).

AI analysis

Story summary

On Tuesday, the shares of US-based ArriVent BioPharma plummeted by nearly 47% after it reported that its cancer treatment firmonertinib failed to meet its primary goal in a phase 3 trial. Firmonertinib was originally developed by Shanghai Allist Pharmaceuticals for treating non-small cell lung cancer with an epidermal growth factor receptor exon 20 insertion mutation. ArriVent had acquired exclusive rights outside of China in 2021, making it one of the first US biotech firms to license Chinese drug assets. This setback highlights the significant risks and challenges that Chinese biotech companies face when expanding into global markets.

Written for “China Biotech Expansion Risks” on 2026-11-04, grounded in this article and the 0 other(s) covering the same event.

Story

📰 China Biotech Expansion Risks
Health · 1 article(s) covering the same event.

Compared with similar articles

Nothing to compare against. No article is close enough to this one for the pipeline to have linked or judged the pair.
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
2
sentences that state something as happening or true
Uncertain
0%
0 of 2 hedged ("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
62/100
South China Morning Post's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
1
Health
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-10-07 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

South China Morning Post · 3707 article(s) · 8 correction(s) detected
Running correction rate · 8 correction(s)
2026-11-03
Singapore hit-and-run: organiser of fund for orphaned boy vows transparency
2026-11-01
Former Apple Daily publisher joins mainland China tour for rehabilitated offenders
2026-10-16
Nobel Peace Prize: the message behind Navi Pillay’s win
2026-10-16
Indonesian governor’s Singapore trip adds fury to forest fire, haze crisis
2026-10-04
Flight to Okinawa diverts back to Hong Kong after suspected landing gear fault
2026-10-04
Tennessee prisons chief resigning after botched execution of Christa Pike
2026-09-29
Indonesian prison chief suspended over secret VIP compound for inmates
2026-09-28
Trump ‘arms offer’ to China jolts Washington into moves to contain the fallout

Who wrote this

Xinmei Shen
12 article(s) here · 0 carrying a prediction
🔮 Beijing-based cancer drug developer InnoCare Pharma said on Thursday that it had entered into a strategic research collaboration and licensing agreement with US pharmaceutical giant Eli Lilly that could be worth up to US$3.35 billion.
2026-09-26 · assertive framing · China’s biotech firms move up value chain as drug deals evolve beyond licensing: analysts
🔮 Rising US scrutiny on clinical trials could threaten China’s biotech advantage: analysts
2026-09-23 · speculative framing · Rising US scrutiny on clinical trials could threaten China’s biotech advantage: analysts
Also by Xinmei Shen
Tokenised gold bar to advance Hong Kong’s ambitions as digital, metal trading hub
2026-11-03 · South China Morning Post
How Hong Kong’s fintech strategy is progressing – and where growth still lags
2026-11-02 · South China Morning Post
Chinese drug sector’s stature grows at major cancer conference
2026-10-28 · South China Morning Post
Former HSBC executive launches wealth platform powered by team of AI agents
2026-10-12 · South China Morning Post
Nothing else under this byline is closely related to this article, so these are simply their most recent.
All 12 articles by Xinmei Shen →

Topics

ArriVent ArriVent BioPharma China Chinese firmonertinib

Subjects

ArriVent ORG · 4× China GPE · 3× Chinese NORP · 3× ArriVent BioPharma ORG · 1× New York GPE · 1× Shanghai Allist Pharmaceuticals ORG · 1×

Narrative

US firm ArriVent’s plunge shows risks facing China’s biotech expansion into global markets US-listed ArriVent lost nearly half its value after a Chinese-licensed cancer drug failed a late-stage trial US firm ArriVent BioPharma’s shares plummeted after a late-stage trial failure involving a cancer drug licensed from China, a setback that analysts said highlighted the challenges facing Chinese biotech companies expanding overseas. New York-listed ArriVent closed down nearly 47 per cent on Tuesday after reporting that its cancer treatment firmonertinib failed to meet its main goal in a phase 3 trial. Firmonertinib was originally developed by Shanghai Allist Pharmaceuticals to treat non-small cell lung cancer (NSCLC), targeting a mutation known as an epidermal growth factor receptor exon 20 insertion.
framing: assertive · carried by 1 article(s) · first seen 2026-10-07
2026-10-07 · South China Morning Post
US firm ArriVent’s plunge shows risks facing China’s biotech expansion into global markets · assertive framing

Claims (2 extracted, 0 hedged)

US firm ArriVent’s plunge shows risks facing China’s biotech expansion into global markets US-listed ArriVent lost nearly half its value after a Chinese-licensed cancer drug failed a late-stage trial US firm ArriVent BioPharma’s shares plummeted after a late-stage trial failure involving a cancer drug licensed from China, a setback that analysts said highlighted the challenges facing Chinese biotech companies expanding overseas. New York-listed ArriVent closed down nearly 47 per cent on Tuesday after reporting that its cancer treatment firmonertinib failed to meet its main goal in a phase 3 trial. Firmonertinib was originally developed by Shanghai Allist Pharmaceuticals to treat non-small cell lung cancer (NSCLC), targeting a mutation known as an epidermal growth factor receptor exon 20 insertion. asserted
Firmonertinib → show → insertion
ArriVent acquired the exclusive rights in 2021 to develop and commercialise the drug outside China, becoming one of the earliest US biotechnology firms licensing Chinese drug assets. asserted
ArriVent → acquire → assets
💬Give feedback
🕘History 🎫Support
Terms · Privacy · beta v2.0.0
Articles to 4 Nov 2026